(MBOT) Microbot Medical Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MBOT) Microbot Medical Inc. Complete Analysis Pack
Microbot Medical’s Business Model: Strategic Blueprint in Brief
Unlock the full strategic blueprint behind Microbot Medical Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, partners strategically, and positions itself in the medical device market. Get the full version for deeper insight and practical analysis.
Partnerships
Stryker Corporation collaboration agreement
Microbot Medical Inc.’s named collaboration with Stryker Corporation links it to 1 major strategic partner for joint work on robotic medical devices. That kind of setup can speed validation, sharpen design feedback, and support a faster path to commercialization.
Stryker reported $22.6 billion in net sales in 2024, so the partnership also gives Microbot access to scale and real-world device development discipline.
Pre-clinical testing partners
Microbot Medical Inc. relies on external pre-clinical labs to test the Liberty system’s safety, performance, and design changes before regulatory review. These partners help turn prototypes into evidence packages for FDA readiness, which is critical because pre-clinical work sits upstream of first-in-human testing and later clinical milestones.
Clinical advisory network
Microbot Medical Inc. uses a clinical advisory network of neurosurgeons and endovascular specialists to refine LIBERTY’s usability, workflow, and procedure fit for minimally invasive robotics. Their input matters because the system is designed for single-operator use in endovascular procedures, so small changes in catheter control and setup can affect time, safety, and adoption.
Patent and regulatory counsel
Microbot Medical Inc. depends on patent and regulatory counsel to keep its 65 patent assets prosecuted and maintained, while also steering device pathway planning for its pipeline. This support matters because Microbot Medical Inc. is advancing regulated medical devices, where patent scope and FDA-style pathway choices can shape speed, cost, and exclusivity.
- 65 patent assets need active prosecution
- Counsel supports device pathway planning
- Protects pipeline value and market access
Future commercialization partners
Microbot Medical Inc. will likely need distributors or larger device partners to reach hospitals, scale manufacturing, and speed market access. That is typical for pre-clinical device firms, especially before a direct sales force is economical; the partner model can cut launch friction and expand surgeon and hospital coverage faster.
- Distributors extend sales reach
- Device partners add manufacturing scale
- Hospital access is the key gating factor
Microbot's Partner Network: Stryker Scale, 65 Patents
Microbot Medical Inc.’s key partners are Stryker Corporation, pre-clinical labs, clinical advisors, patent counsel, and future distributors. Stryker reported $22.6 billion in 2024 net sales, while Microbot Medical Inc. had 65 patent assets to protect and advance.
| Partner | Value |
|---|---|
| Stryker Corporation | $22.6B net sales, 2024 |
| Patent counsel | 65 patent assets |
| Distributors | Scale hospital reach |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas of Microbot Medical Inc. for investors and analysts.
Customizable Excel Spreadsheet
A concise Microbot Medical Inc. Business Model Canvas that highlights how its robotic solutions relieve key surgical pain points.
Reference Sources
Makes Microbot Medical’s analysis more credible by tracing key claims to clear, decision-ready sources.
Activities
Research and device design
Microbot Medical Inc.’s key activity is research and device design for endoluminal surgery, building micro-robotic tools for minimally invasive procedures through concept work, engineering, and repeated iteration. In its latest reported year, the company had no product revenue, so R&D stayed the main operating focus.
Pre-clinical development
Microbot Medical Inc. remains in pre-clinical development, so its core job is to prove prototypes work, are safe, and can be built reliably before later-stage studies. In 2025, that phase still meant no product revenue and a heavy focus on R&D spend, because pre-clinical proof is the gate to human testing.
Pipeline advancement
Microbot Medical Inc. is advancing the LIBERTY single-use robotic system and the Self-Cleaning Shunt while keeping a multi-generational pipeline, so one setback does not derail the whole plan. This spread of programs lowers technical risk and keeps R&D focused on several shots at value creation, not just one.
Intellectual property management
Microbot Medical Inc. treats intellectual property management as a core activity because its portfolio includes 42 granted or allowed patents and 23 pending applications. That portfolio helps defend LIBERTY and related systems, supports future licensing value, and requires ongoing prosecution, maintenance fee tracking, and freedom-to-operate review.
- 42 granted or allowed patents
- 23 pending applications
- Supports defensibility and licensing
Strategic collaboration management
Strategic collaboration management keeps Microbot Medical Inc.’s work with Stryker on track through technical reviews, development planning, and milestone checks. Because the company has limited resources and no broad commercial scale yet, tight coordination helps align internal priorities with partner deliverables and reduce delay risk.
- Align technical reviews
- Track milestones and timing
- Match partner and internal goals
R&D and IP Drive Microbot Medical's 2025 Strategy
Microbot Medical Inc.’s key activities stay centered on R&D for LIBERTY and the Self-Cleaning Shunt, with no product revenue in 2025, so design, testing, and iteration remain the main job. Its 42 granted or allowed patents and 23 pending applications also keep IP work high on the list.
| 2025 | Key Activity | Data |
|---|---|---|
| 2025 | R&D focus | No product revenue |
| 2025 | IP base | 42 granted or allowed; 23 pending |
Preview Before You Purchase
Business Model Canvas
This Microbot Medical Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It’s not a sample or mockup—what you see here is a live snapshot from the final file. Once you buy, you’ll get the same professionally formatted document, ready to review, edit, or present.
Resources
42 granted or allowed patents
Microbot Medical Inc.’s 42 granted or allowed patents are a core strategic asset, protecting its robotic surgery technologies and product concepts. That IP can strengthen partner talks and licensing leverage, while helping defend market position as the company advances its 2025-2026 commercialization plans.
23 patent applications under review
Microbot Medical said it has 23 patent applications under review, which can extend its technology moat and support future product-line protection. The pending filings point to ongoing R&D and a broader pipeline, and if granted they could cover more device generations and strengthen barriers to entry.
ViRob, TipCAT, CardioSert, Liberty
ViRob, TipCAT, CardioSert, and Liberty are Microbot Medical’s proprietary micro-robotic platforms, and they are the core of its endoluminal surgery strategy. These systems support device development across minimally invasive procedures, with the Company’s 2025 filings showing an R&D-led model and no commercial product revenue reported yet.
Self-Cleaning Shunt and single-use robotic system
Microbot Medical Inc.'s Self-Cleaning Shunt and single-use robotic system are named development programs that turn its platform into targeted medical device uses. They sit at the center of the near-term story because Microbot Medical Inc. still reported no product revenue in 2025 filings, so progress on these programs is the main value driver.
- Key resources: two named programs.
Hingham, Massachusetts headquarters
Microbot Medical Inc.'s Hingham, Massachusetts headquarters is the core site for corporate, engineering, and development coordination, so it anchors leadership and day-to-day execution. Founded in 2010, the Company has spent 15+ years building its product, regulatory, and operating capabilities from this base.
- Hingham hub for leadership and execution
- Supports engineering and development work
- Operating base since 2010
Microbot Medical’s Value Is Driven by IP, Not Revenue
Microbot Medical Inc.'s key resources are its 42 granted or allowed patents, 23 pending patent applications, and proprietary ViRob, TipCAT, CardioSert, and Liberty platforms. Its Hingham, Massachusetts base supports R&D and execution, while 2025 filings still showed no product revenue, so IP and development assets remain the main value drivers.
| Resource | 2025/2026 data |
|---|---|
| Granted or allowed patents | 42 |
| Pending patent applications | 23 |
| Product revenue | None reported in 2025 filings |
Value Propositions
Minimally invasive robotic surgery
Microbot Medical Inc. targets endoluminal procedures with micro-robotics, aiming to lower invasiveness versus conventional surgery. Its LIBERTY system, cleared by the FDA in 2024, is built for precise control in confined anatomy, where accuracy can improve access and reduce tissue disruption.
Self-Cleaning Shunt for hydrocephalus
Microbot Medical Inc.’s self-cleaning shunt targets hydrocephalus and normal pressure hydrocephalus, where blocked shunts can force repeat surgery. With hydrocephalus affecting about 1 in 770 U.S. births and NPH estimated in 0.5% to 2% of adults over 65, a design that lowers obstruction risk can improve treatment reliability and reduce care burden.
Single-use endovascular robotic system
Microbot Medical Inc. is building a single-use endovascular robotic system for interventional vascular procedures, designed to support catheter-based work inside blood vessels. By avoiding reuse, it can cut reprocessing steps, help keep workflow more consistent, and support infection control across cases.
Proprietary micro-robotic navigation
Microbot Medical Inc.’s proprietary micro-robotic navigation, led by ViRob, TipCAT, CardioSert, and Liberty, is built to reach hard-to-access anatomy where standard tools struggle. The value is precise navigation, better access, and tighter control in minimally invasive procedures.
- ViRob, TipCAT, CardioSert, Liberty
- Hard-to-reach anatomical spaces
- Navigation, access, control
Protected multi-generational pipeline
Microbot Medical Inc. is not tied to one product idea; its pipeline and patent estate give it multi-path optionality, so one setback does not shut down the story. That matters in a market where the company had $0.1 million in revenue in 2024 and still posted a net loss, making future value more dependent on protected pipeline assets than current sales.
- Multiple paths, not one bet
- Patent protection extends upside
- Supports future commercialization routes
Microbot Medical: FDA-Cleared Robotics for Safer, Precise Procedures
Microbot Medical Inc. sells micro-robotic tools for hard-to-reach procedures, with Liberty cleared by the FDA in 2024 for precise endoluminal navigation. Its self-cleaning shunt and endovascular robot aim to cut repeat surgery risk, reduce reprocessing, and make minimally invasive care more reliable.
| Value driver | Data point |
|---|---|
| LIBERTY FDA clear | 2024 |
| 2024 revenue | $0.1M |
| Hydrocephalus birth rate | 1 in 770 |
Customer Relationships
Strategic co-development
Microbot Medical Inc. uses strategic co-development to pair its internal robotics IP with outside clinical and engineering know-how, which fits a pre-clinical device model. This approach helps it de-risk development across its core Liberty platform while speeding design feedback from partners and surgeons.
Clinical expert feedback
Clinical expert feedback is central for Microbot Medical Inc., because neurosurgeons and endovascular physicians help refine device fit and usability before launch. That early input lowers downstream adoption risk; the Company’s 2025-2026 development work on LIBERTY depends on surgeon-led design choices that can cut costly usability misses later.
Direct B2B engagement
Microbot Medical Inc. sells to hospitals, clinicians, and device partners, so Customer Relationships are direct B2B and built on clinical proof, not retail demand. In FY2025, the Company still had no meaningful product revenue, which fits a long sales cycle where evidence, regulatory progress, and partner trust drive adoption.
Technical validation support
Medical device buyers want proof before they buy, so Microbot Medical Inc. should back sales with demos, bench testing, and workflow training. That validation support lowers adoption risk and helps clinics see how the device fits real use before commercialization.
- Proof of performance
- Demo and test support
- Workflow education
- Builds pre-sale trust
Long-cycle account development
Microbot Medical Inc. builds long-cycle account ties because hospital adoption of a novel robotic system can take years, with each step tied to clinical data, FDA progress, and surgeon training. With no commercial revenue reported in its 2025 filings, the company must keep prospects engaged through study updates and regulatory milestones.
- Years of account nurturing
- Clinical and FDA touchpoints
- Best fit for novel robotics
Hands-On Hospital Sales Need Proof, Demos, and FDA Milestones
Microbot Medical Inc. keeps Customer Relationships highly hands-on: it relies on surgeon feedback, demos, and workflow training to build trust before first sales. That fits a long hospital sales cycle, and FY2025 still showed no meaningful product revenue, so clinical proof and FDA milestones remain the main relationship drivers.
| Metric | FY2025/FY2026 |
|---|---|
| Product revenue | No meaningful revenue |
| Relationship model | B2B, clinical validation |
| Support | Demos, training, feedback |
Channels
Strategic partner channel
Stryker is Microbot Medical Inc.'s clearest named strategic partner channel, and that matters because Stryker reported $22.6 billion in net sales in 2024. A partner of that size can support development, validate the product, and widen future reach, making this route to market central for scale.
Direct hospital and clinician outreach
Microbot Medical Inc. must sell directly to physicians and hospital buyers because medtech adoption depends on hands-on education, technical proof, and trust at the point of care. With the U.S. healthcare system spanning about 6,100 hospitals and more than 1 million physicians, direct outreach helps build early awareness and shortens the path to clinical pilots and procurement.
Clinical trial and study pathways
For Microbot Medical Inc., clinical trials are a key evidence channel: they turn the LIBERTY system into real-world proof for surgeons and hospital buyers. Study sites often become first reference users, and trial data helps support FDA, payer, and reimbursement talks.
Scientific and medical conferences
Scientific and medical conferences let Microbot Medical Inc. meet surgeons, researchers, and investors in one place, which is why pre-commercial medtech firms use them so often. The channel can lift trial awareness, spark partnership talks, and build early adoption interest before broad sales start.
- Reaches key clinical decision-makers
- Fits pre-commercial medtech well
- Supports partnerships and adoption
Corporate and investor communications
Microbot Medical Inc. uses SEC filings, press releases, and investor updates to show progress on its pre-clinical platform and keep the market informed. In 2025, that matters even more for a small public company with no approved product yet, because clear disclosure helps support trust while it works toward clinical milestones and financing.
- SEC filings and updates build confidence.
- Key for a pre-clinical public company.
Stryker, Trials, and SEC Fuel Microbot’s Trust-Building Push
Microbot Medical Inc. relies on partner, direct clinical, conference, and disclosure channels to reach surgeons, hospitals, and investors before full commercialization. Stryker, with $22.6 billion in 2024 net sales, is the key named partner channel, while trial sites and meetings help turn LIBERTY into clinical proof and buyer trust.
| Channel | Why it matters |
|---|---|
| Stryker | Scale and validation |
| Trials, conferences, SEC | Proof, awareness, trust |
Customer Segments
Neurosurgeons
Neurosurgeons are the core clinical buyers for Microbot Medical Inc. because hydrocephalus affects about 1 million Americans, and they decide whether shunt and robotic tools fit real workflow. Their feedback on access, precision, and procedure time helps prove procedural value and shape design for the OR.
Endovascular specialists
Endovascular specialists are a core customer segment because they need fast access, high precision, and short procedure times, and Microbot Medical Inc.'s single-use robotic platform is built to fit that workflow. In the U.S., endovascular care is performed in a large, high-volume setting, so even small gains in control and setup time can matter case after case.
Hospitals and surgical centers
Hospitals and surgical centers are the main buyers, and in the U.S. there are over 6,000 hospitals plus about 6,000 ambulatory surgical centers. They adopt Microbot Medical Inc. only if the device improves outcomes and safety, cuts procedure time or cost, and clearly works for both clinicians and administrators.
Medical device strategics
Medical device strategics are a high-value segment for Microbot Medical Inc. because large medtech firms can use differentiated robotics and IP as a partner path today or an acquisition path later. This matters for licensing and M&A, since the endovascular robotics market is still early and buyers often pay for cleared technology, patents, and clinical data.
- Partners for co-development
- Buyers for IP and robotics
- Supports licensing revenue
- Opens acquisition optionality
Research and clinical opinion leaders
Research and clinical opinion leaders are key for Microbot Medical Inc. because specialized devices often win trust through surgeon-led proof, not mass marketing. Their input can support studies, peer validation, and conference exposure, shaping how the market sees the product before broad adoption.
- Drive peer trust
- Support clinical studies
- Boost conference visibility
- Shape adoption narrative
Who Buys Microbot Medical’s High-Stakes Robotics?
Microbot Medical Inc. serves a narrow, high-stakes buyer set: neurosurgeons and endovascular specialists who judge device fit on access, precision, and procedure time, plus hospitals and ambulatory surgical centers that decide on cost and workflow. Medical device strategics and clinical opinion leaders matter too, because they can fund, validate, license, or acquire the platform.
| Segment | Role | Why it matters |
|---|---|---|
| Clinicians | Use and evaluate | Adoption proof |
| Providers | Buy and deploy | Cost and safety |
| Strategics | Partner or acquire | IP and growth |
Cost Structure
R&D and engineering spend
In 2025, Microbot Medical Inc. remained a pre-clinical robotics developer, so R&D and engineering should be the largest cost bucket; this spend funds design, prototyping, testing, and repeated iteration. Robotics development is capital intensive, and with no commercial revenue yet, cash burn is driven mainly by engineering work rather than sales or manufacturing.
Pre-clinical testing costs
Pre-clinical testing costs for Microbot Medical Inc. cover bench, lab, and validation work, and they climb as the device moves closer to design readiness. These tests are a gate before human studies, so spending stays high until the Company clears safety and performance checks.
IP prosecution and maintenance
Microbot Medical Inc. must fund the filing, prosecution, renewals, and legal defense of 65 patent assets, so IP upkeep is a real fixed cost in its model. Because IP protection is central to company value, these spend lines can rise with more jurisdictions, longer claim battles, and maintenance fees.
Regulatory and quality systems
Microbot Medical Inc. must fund regulatory planning and quality systems early because every new device path needs design controls, risk files, and documented compliance. For a company still aiming at FDA clearance, this overhead is unavoidable and can run before revenue starts, but it reduces approval risk later.
- Compliance costs come before sales
- Quality systems support FDA clearance
- Design control work adds overhead
General and administrative expenses
Microbot Medical Inc.'s general and administrative expenses cover the public-company overhead needed to keep the business listed: leadership, finance, SEC reporting, legal, board work, and admin. For a small medtech company, collaboration and partner management also add cost, so G&A can stay elevated even when product revenue is still limited.
- Leadership and finance costs
- SEC reporting and legal fees
- Board and admin overhead
- Partner and collaboration management
Microbot’s 2025 Costs Were Driven by R&D, Testing, and IP
In 2025, Microbot Medical Inc.’s cost structure was dominated by R&D, pre-clinical testing, IP upkeep, and FDA-ready quality work, because the Company had no commercial revenue and was still pushing LIBERTY through development. G&A stayed high for public-company duties, while 65 patent assets added recurring legal and maintenance spend.
| Cost driver | 2025 signal |
|---|---|
| R&D | Main burn item |
| Testing | Bench and validation |
| IP | 65 patent assets |
| G&A | SEC and admin |
Revenue Streams
Future device sales
Once Microbot Medical Inc. commercializes its devices, future sales of robotic systems and shunts should become the core revenue stream. As of the latest reported 2025 filings, the Company is still precommercial and has not yet built product sales, so device sales would likely be the main operating driver once launches begin.
Collaboration payments
Strategic development agreements can bring upfront funding, milestone cash, or service fees, and that can help Microbot Medical Inc. cut its development burn. If the Stryker relationship is monetized this way, it could add non-dilutive cash while the Company remains in a pre-revenue phase with ongoing 2025 operating losses.
Licensing and royalties
Microbot Medical Inc. can turn its patent portfolio into cash through licensing, and medtech royalty deals often price at about 2% to 8% of product sales. That matters because royalties can pay off even if Microbot Medical Inc. does not fully commercialize the device itself, so IP alone can become a revenue stream.
Single-use consumable sales
Microbot Medical Inc.’s single-use consumable model is built for repeat unit economics: each procedure can drive a new disposable sale, not just a one-time device sale. In its latest filings, Microbot Medical remained pre-commercial with no meaningful product revenue, so recurring demand still depends on launch and hospital adoption.
- Per-procedure sales can repeat every case.
- Disposables fit hospital-based workflows.
- Revenue scales with procedure volume.
Potential milestone-based income
Microbot Medical Inc. is still pre-revenue, so potential milestone-based income would likely come only when a partner pays for technical, regulatory, or delivery checkpoints rather than from product sales. That makes this stream highly execution-driven; as of the latest public filings I know, Company Name reported 0 product revenue, so any cash inflow here would depend on hitting specific contract milestones.
- Pay on technical progress
- Trigger on regulatory wins
- Depend on partner terms
Microbot Medical’s Revenue Is Still a Future Story
Microbot Medical Inc.’s revenue streams are still mostly future-facing: device sales, disposables, licensing, and milestone fees. In latest 2025 filings, the Company remained precommercial with 0 product revenue, so cash still depends on development execution and partner deals.
| Stream | 2025 status |
|---|---|
| Product sales | 0 revenue |
| Licensing/royalties | Potential |
| Milestones/service fees | Potential |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.